← Back to Clinical Trials
Recruiting NCT03890614
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
Trial Parameters
Condition Hematologic Malignancy
Sponsor Wake Forest University Health Sciences
Study Type OBSERVATIONAL
Phase N/A
Enrollment 70
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2019-05-16
Completion 2027-02
Interventions
Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates
Brief Summary
The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.
Eligibility Criteria
Inclusion Criteria: * Patients with suspected or confirmed hematologic malignancy undergoing a bone marrow biopsy as part of their care. * The ability to understand and willingness to sign an IRB approved informed consent document.
Related Trials
NCT06532773
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients
View Trial →
NCT05529069
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Pa
View Trial →
NCT05882175
Prospective Validation of the OHI Index
View Trial →